Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)

BackgroundNeoadjuvant chemotherapy combined with PD-1 inhibitors has shown application potential in esophageal squamous cell carcinoma (ESCC), however, optimization strategies for administration timing (sequential vs. concurrent) still lack support from prospective evidence.MethodsThis open-label, phase II randomized controlled trial enrolled a total of 70 patients with resectable locally advanced ESCC from July 2019 to June 2023.

Patients were randomized 1:1 to the sequential group (paclitaxel/cisplatin on day 1, toripalimab on day 3) or the concurrent group (all drugs on day 1). The primary outcome was pathological complete remission (pCR).

The secondary outcomes were to explore the safety of chemotherapy combined with toripalimab as neoadjuvant treatment under different administration sequences, evaluating treatment-related adverse events (AEs), overall survival (OS) and disease-free survival (DFS).ResultsAll 70 patients completed neoadjuvant treatment, and 54 patients underwent surgery. The overall pCR rate was 22.2% (12/54), with no significant difference between the sequential group and the concurrent group (17.8% vs.

26.9%, P = 0.636). In terms of safety, the incidence of grade 3–5 TRAEs was 14.2% (10/70).

The concurrent group had significantly higher incidences of nausea and diarrhea (P<0.05).